Pharmaceutical market structure
|
|
- Neal Adams
- 5 years ago
- Views:
Transcription
1
2 Pharmaceutical market structure Russian pharmaceutical market volume in 2015 ~ billion, RUR* / 17,3 billion $* Consumer money State budget RETAIL 66,6 % 13,5 % Reimbursement 16% % 4% Retail 67% *Excluding biologically active additives (BAA) and additional assortment 17% Source: AlphaRM analytical database Hospital Reimbursement Target segment 13% 4% 66% % 3,9 % Hospitals Target segment** State procurement **Specially allocated funds
3 Russian market. General economic indicators Gross national product at current prices (nominal) ,2 % Gross national product in constant prices (in 2011 prices) ,9 % - 22,6 % Russian GDP, billion, RUR Russian GDP, billion, $ Russian GDP, billion, - 3,7 % ,3 % - 27,8 % Russian GDP, billion, RUR Russian GDP, billion, $ Russian GDP, billion,
4 Russian market. General economic indicators Inflation,% RUR ,9 11,36 6,1 6,58 6, Dynamics of the average salary % ,4 % ,1 % Average salary, RUR Average salary, $ Average salary,
5 Russian pharmaceutical market indicators Total market*, billion, RUR + 11,2 % + 13,2% Target segment Reimbursement Hospital Retail Total market*, billion, units - 2,2 % - 2 % ,2% - 26,5 % -12,6% Total market, RUR, billion Total market, $, billion Total market,, billion Source: AlphaRM analytical database *Excluding biologically active additive (BAA) and additional assortment
6 Russian pharmaceutical market. Pharmaceutical manufacturers rating 8 companies from TOP 10 grew up or stagnated in national currency in 2015 TOP 10 Other Company MS,% RUR, 2015 NOVARTIS (Switzerland) 5,24 PHARMSTANDART (Russia) 4,42 SANOFI (France) 4,01 TAKEDA (Japan) 3,03 BAYER (Germany) 2,86 Abbott (USA) 2,56 SERVIER (France) 2,55 Johnson & Johnson (USA) 2,37 STADA (Germany) 2,33 TEVA (Israel) 2,24 Source: AlphaRM analytical database
7 Retail. Pharmacies structure Pharmacy retail segment value ~ 927* billion rubles 1 st Q st Q 2016 Federal chains 22% 14% 17% 12% Regional chains Local chains 22% 15% 16% 14% Small local chains 35% Single pharmacies 33% TOTAL 50,6K +9,3 % TOTAL 55,3K *Including biologically active additives (BAA) and additional assortment Source: AlphaRM analytical database
8 Pharmacy chain Number of pharmacies Rigla (Moscow) (Moscow) A5 Group (Moscow) Planeta zdorovya (Perm) 901 Doctor Stoletov & Ozerki (Moscow) 292 Pervaya pomosch & Raduga (St. Petersburg) Imploziya (Samara) Pharmaimpex (Izhevsk) 589 Pharmland (Ufa) 585 Farmakopeyka & Tvoi doctor (Tula) 531 Pharmacy chain Retail. Pharmacies structure Pharmacy retail segment value ~ 927* billion rubles 1 st Q st Q 2016 *Including biologically active additives (BAA) and additional assortment Number of pharmacies MS, RUR Rigla (Moscow) , (Moscow) ,32 Planeta zdorovya (Perm) 950 2,53 Doctor Stoletov & Ozerki (Moscow) 312 2,51 Pervaya pomosch & Raduga (St. Petersburg) ,49 Imploziya (Samara) , 42 Pharmaimpex (Izhevsk) 592 1,61 Farmakopeyka & Tvoi doctor (Tula) 581 1,60 Neo-Pharm (Moscow) 240 1,53 Pharmland (Ufa) 625 1,53 Source: AlphaRM analytical database
9 Retail. Main indicators RX drugs grew more than OTC, share of imported drugs has not changed significantly RX OTC Other Essential drug list + 12,1 % 37,19% + 11,3% 36,90% 49,40% 48,93% + 14,1 % 50,60% 51,07% + 13,7% 62,81% 63,10% % 69% Import Local + 11,8 % + 16,1 % 32% 68%
10 Retail. Dynamics For the first three months of the year: growth in rubles ~ 1,1%, reduction in units ~ 8% RUR Units Billion, RUR Mln. - 5 % + 6,8% +2,8% JANUARY FEBRUARY MARCH - 7,2% - 3,7% - 14,7% JANUARY FEBRUARY MARCH Source: AlphaRM analytical database
11 State procurement. Structure State segment shows small but steady growth in national currency ,4 % Target segment Reimbursement Hospital Billion, RUR Hospitals Reimbursement Target segment (Specially allocated funds) > stationary hospital, > outpatient clinic High-cost nosology, ONLS program, Regional reimbursement Federal and regional target (special -purpose) program, Departmental and social institutions 47,8 % 40,4 % 11,8 %
12 State procurement. Main indicators RX OTC 5,09% 1,25% 2,69% 29,68% Essential drug list Other 20,92% 17,17% 94,91% 98,75% 97,31% 70,32% 79,08% 82,83% Hospital Reimbursement Target market Hospital Reimbursement Target market % 81% + 3 % Import + 27 % Local 22% 78%
13 Dynamics of state procurement market Completed tenders value Mln., RUR October November December January February March Source: AlphaRM analytical database
14 Russian pharmaceutical market. Dynamics ,3 239,7 251,9 325,2 235,7 Q1 2015/ Q ,2 % State segment Retail segment Billion, RUR Q Q Q32015 Q Q Source: AlphaRM analytical database
15 Russian total market general economic indicators. Forecast Inflation,% 11,36 12,9 8,78 6,45 6,1 6,58 7, F Russian GDP (nominal) % ,1 % ,6 % Russian GDP, billion, RUR Russian GDP, billion, $ F 1000 Russian GDP, billion,
16 Russian pharmaceutical market Forecast 2016 The pharmaceutical market will exceed billion rubles* in % /+ 10 % + 11,2 % Billion, RUR F - 2,2 % - 1 % / -6 % Target segment Reimbursement Hospital Retail Billion, Units F
17 Russian pharmaceutical market Forecast 2016 The pharmaceutical market will increase by 3% - 10% in rubles* in ,5 % + 6 % ,2 % - 2,8 % Total market, RUR, billion Total market, $, billion Total market,, billion ,6 % - 3,2 % F 14 *Excluding biologically active additive (BAA) and additional assortment
18 Main trends for the year 2016 Retail segment: growth of the pharmacy chains segment share; consolidation of wholesale (distribution) segment; market growth while reducing the purchasing power of consumers; reorientation of consumers to purchase more cheaper analogues or generics. State segment: decreasing of the share of imported medicines in the structure of purchases (in the framework of the program of "Import substitution", in particular the adoption of the so-called Odd man out" resolution); reduction in funding regional target and reimbursement programs; waiting for starting of pilot projects of the pharmaceutical insurance system.
19 Thank you for your attention!
Facts from IQVIA M Copyright 2017 IQVIA. All rights reserved.
Facts from IQVIA M01 2018 Copyright 2017 IQVIA. All rights reserved. Russia pharma market growth in January 2018 Market decreases by -19% in value and -8,3% in volume VALUE, BLN RUB VOLUME, BLN PACKS 90-19%
More informationRussian market at a crossroads: still emerging and attractive, despite going through hard times
Russian market at a crossroads: still emerging and attractive, despite going through hard times Nickolai Demidov General manager IMS Health Russia&CIS 15.9.215 Executive summary Market overview Russian
More informationFacts from IQVIA M Copyright 2017 IQVIA. All rights reserved.
Facts from IQVIA M07 0 Copyright 07 IQVIA. All rights reserved. Russia pharma market growth in January-July 0 Market grew by,% in value and decreased by,4% in volume VALUE, BLN RUB VOLUME, BLN PACKS +,%
More informationThe Russian pharmaceutical market. Marina Veldanova Managing Director Polpharma Russia
The Russian pharmaceutical market Marina Veldanova Managing Director Polpharma Russia EGA ANNUAL CONFERENCE - ISTANBUL JUNE 2007 Agenda: 1. Russian pharmaceutical market vs. another ones. 2. RPhM s structure
More informationPrice regulation models in Turkey and the Russian Federation. Panos Kanavos London School of Economics NPPA Seminar, New Delhi, April 2008
Price regulation models in Turkey and the Russian Federation Panos Kanavos London School of Economics NPPA Seminar, New Delhi, April 2008 The context: Why Turkey and Russia? Attribute Implementing Health
More informationFacts from IQVIA M Copyright 2017 IQVIA. All rights reserved.
Facts from IQVIA M10 2018 Copyright 2017 IQVIA. All rights reserved. Russia pharma market growth in January-October 2018 Market grew by 3, in value and decreased by 2,9% in volume VALUE, BLN RUB VOLUME,
More informationBackground Distribution and Safety Issues in the United States Consumer Advertising/Promotion World Health and Life Expectancy
CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION Background Distribution
More informationCOMPANY PROFILE SEPTEMBER 2010
COMPANY PROFILE SEPTEMBER 2010 DISLAIMER THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION. NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA,
More informationRussian market evolvement in crisis mode, first insights of 2016 and further outlook. Demidov Nickolai General manager IMS Health, Russia&CIS
Russian market evolvement in crisis mode, first insights of 2016 and further outlook Demidov Nickolai General manager IMS Health, Russia&CIS 1 Whole market Russian pharmaceutical market grew by 10% terms
More informationDrug Reimbursement - Croatia. Roganovic Jelena
Drug Reimbursement - Croatia Roganovic Jelena Population: 4,292,095 (July 2017) Area: 56,594 km 2 Density: 75.8/km 2 21 counties http://www.lokalniizbori.com/wp-content/uploads/2013/04/hrvatska-%c5%beupanije.jpg;
More informationPharmacy Chain 36.6 COMPANY PROFILE. August 2008
Pharmacy Chain 36.6 COMPANY PROFILE August 2008 1 DISCLAIMER THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION, AND IS NOT AN OFFER TO SELL, OR AN INVITATION TO MAKE OFFERS
More informationOJSC «VEROPHARM» ANNOUNCES FINANCIAL RESULTS OF 2013
PRESS-RELEASE FOR IMMEDIATE DISTRIBUTION APRIL 30, 2014 OJSC «VEROPHARM» ANNOUNCES FINANCIAL RESULTS OF 2013 April 30, 2014, MOSCOW OJSC «VEROPHARM» [RTS:VRPH, MICEX:VFRM] announces its audited financial
More informationOriola KD Corporation January March Eero Hautaniemi President and CEO 25 April 2013
Oriola KD Corporation January March 2013 Eero Hautaniemi President and CEO 25 April 2013 Key Figures in January March 2013 Q1 2013 Q1 2012 Change % Net sales, Me 612 591 3.6 % Operating profit, Me 2.3
More informationFREE ARTICLE. Russian pharmaceutical market overview. Source: Pharma Poland News
FREE ARTICLE Russian pharmaceutical market overview Source: Pharma Poland News July 2006 Last year, the Russian pharmaceutical market expanded at an unprecedentedly high rate of 35%, much higher than the
More informationImproving data on pharmaceuticals. Meeting of OECD Health Data National Correspondents 3-4 october 2011
Improving data on pharmaceuticals Meeting of OECD Health Data National Correspondents 3-4 october 2011 Purpose of this agenda item Present the current content of OECD health data on pharmaceuticals Propose
More informationPharma market outlook in the background of stabilization observed in 2016
Pharma market outlook in the background of stabilization observed in 8 th of February 2017 Demidov Nickolai, GM QuintilesIMS, Russia&CIS Copyright 2017 QuintilesIMS. All rights reserved. Contents Key macro
More informationGlobal Health and the role of biopharma. Adapting the Innovation Landscape UK Biopharma R&D Sourcebook 2015
Global Health and the role of biopharma Adapting the Innovation Landscape UK Biopharma R&D Sourcebook 2015 Health Expenditure as a % of GDP 3.1 The growth of total expenditure on health as a share of gross
More informationFood supplements as part of the OTC Market
1/16/218 Food supplements as part of the OTC Market Hynek Valerián, IQVIA Copyright 218 IQVIA. All rights reserved. + Global and European context for OTC market Table of Contents + Czech Republic OTC and
More informationOriola KD Corporation. Carnegie Lunch Seminar Helsinki, 11 May 2012
Oriola KD Corporation Eero Hautaniemi President & CEO Oriola KD Corporation Joni Ihantola Vice President, Treasury & IR Oriola KD Corporation Carnegie Lunch Seminar Helsinki, 11 May 2012 Key Figures Q1
More informationNational Trends in Per Capita Pharmaceutical Spending,
Exhibit 1 National Trends in Per Capita Pharmaceutical Spending, 1980 2015 $1,200 $1,000 United States Switzerland Germany $800 Canada France $600 $400 United Kingdom Australia Netherlands Norway Sweden
More informationJoint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group MACROECONOMIC INDICES Inflation According to Federal State Statistics Service s data, the
More informationMACROECONOMIC INDICATORS OF RUSSIA
MACROECONOMIC INDICATORS OF RUSSIA 2007 2011 by Prof. Dr. Mstislav AFANASIEV rector www.abik.ru February 2011 GDP in Russia and Japan Source: International Monetary Fund, World Economic Outlook Database,
More informationCOMPETITIVE POSITIONING OF THE TOP 10 PLAYERS GROWING ALLIANCES IN BIOPHARMACEUTICALS TABLE 7 KEY LICENSING AND PARTNERSHIP DEALS IN
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 2 INTENDED AUDIENCE... 3 METHODOLOGY AND INFORMATION SOURCES... 3 ANALYST CREDENTIALS...
More informationInterim Report on the First Three Months 2017 Brands for People
Interim Report on the First Three Months 2017 Brands for People 02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million 3 months 2017 Jan. 1 Mar. 31 3 months 2016 Jan. 1 Mar. 31 ± %
More informationDrug Pricing in Japan
Drug Pricing in Japan ISPOR Asia Pacific Conference IP1: Cost vs Value: What is the fair price of a drug? 2018.9.9 Takashi Fukuda, PhD Director Center for Outcomes Research and Economic Evaluation for
More informationForeign Direct Investment in the Health Care Sector in Developing Countries Locations and Governance
Foreign Direct Investment in the Health Care Sector in Developing Countries Locations and Governance J. François Outreville UNCTAD, Division on Investment, Technology and Enterprise Development 1 FDI and
More informationNational Pharmaceutical Sector Form of Mongolia
National Pharmaceutical Sector Form of Mongolia Date: 12 August, 2004 Population: 2 476 644 Daily wage of lowest paid government worker 2292.9 Rate of exchange (commercial buy rate) to US dollars on the
More informationPharmacy sales, $ mil. (wholesale prices) July Growth gain, % (roubles) Region. September/ July/ June 18. August.
MACROECONOMIC INDICES Inflation According to Federal State Statistics Service s data, the Consumer Price Index was estimated as 1.4% in October, compared to the previous month, and 12.5% against December.
More informationFederal Spending on Brand Pharmaceuticals. April 2011
Federal Spending on Brand Pharmaceuticals April 2011 Summary Avalere Health estimates that manufacturers of brand-name prescription drugs will receive about $777 billion in revenues from the sales of outpatient
More informationThe Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE**
The Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE** Pharmaceutical, commercial and strategic developments in the Brazil, Russia, India & China Over-the- Counter
More informationAssessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing Exemption in the EU
White paper Assessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing Exemption in the EU Ramya Logendra, Engagement Manager, Supplier and Association Relations Per
More informationCurrent trends in generic medicines in the Middle East: challenges and opportunities. Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC
Current trends in generic medicines in the Middle East: challenges and opportunities Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC Middle East and North African pharmaceutical markets Middle
More informationGROUP EBITDA UP 256% IN 1H 2009 VERSUS 1H 2008
PRESS-RELEASE FOR IMMEDIATE DISTRIBUTION OJSC PHARMACY CHAIN 36.6 REPORTS Q2 AND 1H 2009 UNAUDITED IFRS RESULTS GROUP EBITDA UP 256% IN 1H 2009 VERSUS 1H 2008 September 24, 2009, MOSCOW OJSC Pharmacy Chain
More informationPharmaceutical Product supply chain in figures
Pharmaceutical Product supply chain in figures Gorlova Irina, SMD Director General Presentation for Press Club of Pharma Net Pharmaceutical Product supply chain SMD (Support in Market Development). Marketing
More informationProf. Claude Farrugia Vice President Communications, EIPG
Prof. Claude Farrugia Vice President Communications, EIPG Is the storm over? Malta, 2008 Is the storm over? Malta, 2008 Is the storm over? Malta, 2008 Drug Development is Risky Drug Development is a Costly
More information2016 Results Summary. Press Conference, Warsaw, 16 th March 2017
2016 Results Summary Press Conference, Warsaw, 16 th March 2017 AGENDA 2016 Summary Market Environment and Financial Results Forecast Performance and Profit Share Pro-patients Businesses Perspectives for
More informationMACRO-ECONOMICS REGULATORY INFRASTRUCTURE PHARMA INDUSTRY
MACRO-ECONOMICS Economic growth are potentially good GDP per capita above $ 3.000 Government health budget increases to 5% Middle class category is projected into 150 Mn in 2014, average life expectancy
More informationPerspectives on Russia & Ukraine
Perspectives on Russia & Ukraine Antonio Melo Chief Operational Officer IGD Conference Global Retailing 08 New Horizons, Bright Ideas London, May 2008 p. 1 Russian Food Retail Market is One of the Fastest
More informationPHARMSTANDARD LEADING RUSSIAN PHARMACEUTICAL COMPANY. Company Profile -2009,1Q2010
PHARMSTANDARD LEADING RUSSIAN PHARMACEUTICAL COMPANY Company Profile -2009,1Q2010 About Pharmstandard Business & Financial Results Presentation for Investors 6/23/2010 2 Pharmstandard at Glance Leading
More informationPharmaceutical Pricing and Reimbursement A Global Perspective. Andreas Seiter The World Bank PPRI Conference, September 2011
Pharmaceutical Pricing and Reimbursement A Global Perspective Andreas Seiter The World Bank PPRI Conference, September 2011 The World Bank and its Clients Financing (IDA, subsidized) Low-Income Countries
More informationTaiwan OTC market overview. The opportunities and challenges in OTC. Future outlook
1 2 Taiwan OTC market overview The opportunities and challenges in OTC Future outlook Taiwan OTC market overview 3 4 Taiwan Pharmaceutical market Taiwan pharmaceutical market is dominated by prescription
More informationLudmila Maksimova, PhD «Center for Health Technology Assessment» PANEPA Executive Director of ISPOR Russia HTA Chapter
CURRENT STATE OF HEALTHCARE FUNDING IN THE RUSSIAN FEDERATION: TRANSITION TO ONE-CHANNEL FUNDING ISPOR 17TH ANNUAL EUROPEAN CONGRESS 8-12 NOVEMBER 2014 AMSTERDAM RAI AMSTERDAM, THE NETHERLANDS Ludmila
More informationSTADA: Growth after nine months of 2006: Sales +18%, adjusted net income +27%
Corporate News STADA: Growth after nine months of 2006: Sales +18%, adjusted net income +27% Important items at a glance Nine-month figures 2006 confirm sustainable growth: o Group sales EUR 870.3 million
More informationUkrainian Pharmaceutical Market
Ukrainian Pharmaceutical Market March 2013 SMD Monthly Review SMD Analytics and Country Survey Ukraine *smd.net.ua/en* +380 44 206 1717/18 10.05.2013 SMD Monthly Review Ukraine. March 2013 2 Definitions
More informationDistribution of medicines in the Czech Republic
12/4/217 Distribution of medicines in the Czech Republic Hynek Valerián Copyright 217 IQVIA. All rights reserved. Czech pharmaceutical market 1 1 12/4/217 Terminology note Rx-bound medicines/otc medicines
More information30 August 2017 г., Moscow, Russia PRESS-RELEASE
4, Yakimanskaya quay, Bldg. 1, Moscow, Russia, 119180 Tel.: +7 495 510-26-95 Fax: +7 495 510-26-97 e-mail: info@belugagroup.ru 30 August 2017 г., Moscow, Russia PRESS-RELEASE announces its 1H2017 financial
More informationNicholas Hall s Global OTC Markets The Definitive Guide to the World s 12 Leading OTC Markets
Nicholas Hall s Global OTC Markets The Definitive Guide to the World s 12 Leading OTC Markets Canada USA UK France Germany Italy Russia China Japan India Brazil Australia Global OTC Markets The Definitive
More informationRMG Research, November 16, 2010 Ksenia Arutyunova, Ekaterina Andreyanova (7 495)
Company Report Pharmaceuticals Diod: Small and ambitious Investment Summary DIOD HOLD $1.1 10% We start coverage of Diod, Russia s #2 consumer health producer, which held an IPO in June. Diod is focused
More information2016 Results Summary. Warsaw, 16 th March 2017
2016 Results Summary Warsaw, 16 th March 2017 AGENDA 2016 Summary Market Environment and Financial Results Forecast Performance and Profit Share Pro-patients Businesses Perspectives for 2017 2016 Summary
More informationThailand Market Report
Thailand Market Report The macro environment is positive for the Thai pharmaceutical market. Economically, the Economist Intelligence Unit (EIU) projects that Thailand will be the eighth largest economy
More informationCoping With Increasing Health Care Expenditures. Henry J. Aaron and M. James Kondo
Coping With Increasing Health Care Expenditures By Henry J. Aaron and M. James Kondo Some basic health economics 1. Controlling the level and growth of health care spending is a problem in every developed
More informationBudget restrictions of the Russian economic development in long-term prospect
Institute of Economic Forecasting, Russian Academy of Sciences Budget restrictions of the Russian economic development in long-term prospect Performed by Savchishina Ksenia Institute of Economic Forecasting
More informationRenee Gravalin, Partner
Experience the Eide Bailly Difference 340B Drug Program Renee Gravalin, Partner rgravalin@eidebailly.com 701.799.5449 Agenda Proposed Changes 1 Experience the Eide Bailly Difference Created in 1992 to
More informationIMS Retail Drug Monitor
IMS Retail Drug Monitor Tracking 13 Key Global Pharma Markets 12 months to November 2004 Regional Sales Breakdown: $US Billions 200 10% 180 Value US$Bill 160 % Growth IMS HEALTH, the global healthcare
More informationMedicare 101 Nov. 9, Greg Burn
Medicare 101 Nov. 9, 2016 Greg Burn Important Note The Centers for Medicare and Medicaid Services (CMS) regulations change on a regular basis. The information in this presentation is provided for general
More informationFOR IMMEDIATE RELEASE 19 March 2010 A&D PHARMA HOLDINGS N.V. UNAUDITED FINANCIAL STATEMENTS FOR THE 12 MONTHS ENDED 31 DECEMBER 2009
FOR IMMEDIATE RELEASE 19 March 2010 A&D PHARMA HOLDINGS N.V. UNAUDITED FINANCIAL STATEMENTS FOR THE 12 MONTHS ENDED 31 DECEMBER 2009 18% year-on-year RON denominated consolidated sales growth 3% year-on-year
More informationPodravka Group business results. for period
Podravka Group business results for 1-12 2014 period 1 12 2014 Significant events SBA Food and Drinks SBA Pharmaceuticals Financial statements Share Significant events in 2014 Decision of Croatian Health
More informationRecent Developments In U.S. Pharmaceutical Pricing: The Case Example Of The Proposed Medicare Part B Experiment
Recent Developments In U.S. Pharmaceutical Pricing: The Case Example Of The Proposed Medicare Part B Experiment Presentation by Susan Dentzer President and CEO, NEHI (Network for Excellence in Health Innovation)
More informationEuropean attractiveness survey 2016 Russia findings
European attractiveness survey 2016 Russia findings European context: Western Europe continues to be the most appealing FDI destination in Europe Despite a number of geopolitical risks, investors continue
More informationInvestor Relations & Capital Markets
Investor Relations & Capital Markets Forward-Looking Statements Some of the information in this presentation is not historical in nature and may constitute forwardlooking statements, which are made pursuant
More informationVIETNAM PHARMACEUTICAL INDUSTRY REPORT Q4/2017
VIETNAM PHARMACEUTICAL INDUSTRY REPORT Q4/2017 1 Content Executive Summary 4 1. Business Environment 6 1.1 Macroeconomic Situation 6 1.2 Legal Barriers 10 1.3 Impacts of Free Trade Agreement 18 2. Vietnam
More informationPharmaceutical Management Medicaid 2017
Pharmaceutical Management Medicaid 2017 Customer Service: (888) 327-0671 TTY: 711 Pharmacy Administration: (810) 244-1660 Visit our website at: McLarenHealthPlan.org MHP42721056 5/2017 Introduction Pharmaceutical
More informationDrug Pricing & Reimbursement in Qatar
Drug Pricing & Reimbursement in Qatar Daoud Al-Badriyeh, PhD Assistant Professor of Pharmacoeconomics College of Pharmacy Qatar University Doha, Qatar Drug Pricing in Qatar - History Law No. (7) of 1990,
More informationTeam: Anastasiia Ivanova Olga Kotelnikova Alina Luchinina Tatiana Rubtsova
Team: Anastasiia Ivanova Olga Kotelnikova Alina Luchinina Tatiana Rubtsova Current strategy of Ryazan Capital Bank does not support the goal of maximizing return on equity Financial results Customers Revenue
More informationMarket growth potential in Turkey: Short & medium term evaluation. Cem Baydar, Country Principal Istanbul, September, 2010
Market growth potential in Turkey: Short & medium term evaluation Cem Baydar, Country Principal Istanbul, September, 2010 With more than 1700 consultants, IMS has evolved since 2003 to be the #1 company
More informationSTADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41%
Corporate News STADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41% STADA interim report after 9 months of 2007: Important items at a glance Strong operative growth continues as expected
More informationPolicies to contain public pharmaceutical expenditure by acting not only on the supply-side but on the demandside
Stella Kanellopoulou, PhD Research Economist skanellopoulou@eurobank.gr DISCLAIMER This report has been issued by Eurobank Ergasias S.A. ( Eurobank ) and may not be reproduced in any manner or provided
More informationX5 + Karusel. Transforming the Russian Food Retail Landscape. 11 April 2008
X5 + Karusel Transforming the Russian Food Retail Landscape 11 April 2008 Compelling Investment Proposition Significant Step-Up in Scale of X5 s Business Immediate Position as a Leading Hypermarket Operator
More informationInterim Report on the First Six Months and the Second Quarter of 2017 Brands for People
Interim Report on the First Six Months and the Second Quarter of 2017 Brands for People 02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million Q2/2017 1) Q2/2016 ± % H1/2017 1) H1/2016
More informationJune 3 rd 2015, Koprivnica, Croatia. Podravka Inc. General Assembly
June 3 rd 2015, Koprivnica, Croatia Podravka Inc. General Assembly Key highlights of 2014 SBA Food and Drinks in 2014 SBA Pharmaceuticals in 2014 Financial reports in 2014 Short overview of 1-3 2015 Significant
More informationPharmaceutical Management Commercial Plans
Pharmaceutical Management Commercial Plans 2015 Toll Free Contact Number: (888) 327-0671 Medical Management: (810) 733-9711 Visit our website at: MclarenHealthPlan.org Introduction Pharmaceutical Management
More informationHEALTH CARE MODELS: INTERNATIONAL COMPARISONS
HEALTH CARE MODELS: INTERNATIONAL COMPARISONS Dr. Jaime Llambías-Wolff, Ph.D. York University Based and adapted from presentation by : Dr. Sibu Saha, MD, MBA Professor of Surgery University of Kentucky
More informationFirst Balkan Forum on: Health Care Reform
First Balkan Forum on: Health Care Reform ALBANIA: AN OVERVIEW of THE HEALTH SYSTEM & HEALTH INSURANCE SCHEME Ms. Elvana Hana General Director Albanian Health Insurance Institute November 2007 1 Albania
More informationLeadership In Russian Food Retail March 2008
Leadership In Russian Food Retail March 2008 p. 1 Disclaimer This presentation does not constitute or form part of and should not be construed as an advertisement of securities, an offer or invitation
More informationFirst Quarter Interim Management Statement. 11 April 2011
First Quarter Interim Management Statement 11 April 211 Michael Page International First Quarter Interim Management Statement 2 Group Gross profit +29% with growth in every geography Growth Rates Group
More informationKEY FIGURES OF THE PHARMACEUTICAL
KEY FIGURES OF THE PHARMACEUTICAL 54.1 Billion Revenue (expressed as manufacturer's price before tax) generated in France by pharmaceutical companies in 2017, of which 25,1 Billion from exports. 4.5 Billion
More informationPHARMACEUTICAL PRICING AND REIMBURSEMENT SYSTEM IN SPAIN
PHARMACEUTICAL PRICING AND REIMBURSEMENT SYSTEM IN SPAIN Dirección General de Farmacia y Productos Sanitarios 1 Mercedes Martínez Vallejo, Head of Economy of Pharmaceuticals LEGAL FRAMEWORK General Health
More informationInsurance & Medication Access
Insurance & Medication Access Ontario Rheumatology Association 12th Annual Meeting JW Marriott The Rosseau Muskoka May 25, 2013 Suzanne Lepage, Private Health Plan Strategist Learning Objectives Understand
More informationOTC market in Russia Development forecasts for
2 Language: English Date of publication: Delivery: pdf Price from: 950 October 2015 Find out What is the saturation of the OTC market in Russia? How are OTC manufacturers planning to achieve future growth?
More informationSTADA KEY FIGURES. 02 STADA Key Figures. 6 months 2015 Jan. 1 June 30 ± % 6 months 2016 Jan. 1 June 30. Key figures for the Group in million
02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million 6 months 2016 Jan. 1 June 30 6 months 2015 Jan. 1 June 30 ± % Group sales 1,034.7 1,025.9 +1% Generics (core segment) 603.8 615.3-2%
More informationBALANCE OF PAYMENTS¹ of the Republic of Azerbaijan for January September, 2015
BALANCE OF PAYMENTS¹ of the Republic of Azerbaijan for January September, 2015 As in previous years, in January - September, 2015 external economic operations had positive balance on the oil-and-gas sector
More informationSTADA: Strong growth continues in H1/2007 sales +27%, net income +38%
Corporate News STADA: Strong growth continues in H1/2007 sales +27%, net income +38% Important items at a glance Group sales increase by 27% to EUR 737.4 million in H1/2007 Net income grows by 38% to EUR
More informationThe need for generic policies as part of health reform. Richard Laing EMP/WHO for Geneva 2013
The need for generic policies as part of health reform Richard Laing EMP/WHO for Geneva 2013 Even after patent expiration brands still retain a sizeable volume share in some countries VOLUME MARKET SHARE
More informationAndreas Seiter, World Bank
Pharmaceutical Pricing and Reimbursement Inputs from a Global Perspective Vienna, June 2007 Andreas Seiter, World Bank World Bank support for health systems development Loans for capacity building through
More information2009 UBS Healthcare Services Conference
2009 UBS Healthcare Services Conference February 10, 2009 John H. Hammergren Chairman and Chief Executive Officer Safe Harbor Clause Some of the information in this presentation may constitute forwardlooking
More informationFee Schedule for NSD s Depository Services
Fee Schedule for NSD s Depository Services Section 1. General Provisions 1.1. This Fee Schedule for NSD s Depository Services (the Fee Schedule ) sets out fees payable for depository services provided
More informationInstitutional Presentation. June/2016
V2 Institutional Presentation June/2016 Disclaimer This release contains forward-looking statements that are exclusively related to the prospects of the business, its operating and financial results, and
More informationNew Models, New Metrics for Generics. IGPA Conference Montreal October 1 st 2009
New Models, New Metrics for Generics IGPA Conference Montreal October 1 st 2009 Current Environment Improving but 1 Stakeholders Patients Effects Price conscious and value for money Selecting cheaper drugs
More informationCANM-CAMRT JOINT ANNUAL CONFERENCE MARCH 22-24, 2018 VANCOUVER, B.C.
CANM-CAMRT JOINT ANNUAL CONFERENCE MARCH 22-24, 2018 VANCOUVER, B.C. I do not have a financial interest, arrangement or affiliation including receipt of honoraria or expenses with a commercial organization
More informationApril Newsletter
April 2011 Newsletter The Russian pharmaceutical market is one of the most dynamic and fast growing in the world. According to a forecast of the Ministry of Industry and Trade of the Russian Federation,
More information340B Drug Pricing Program
340B Drug Pricing Program Mary Stepanyan, PharmD Candidate 2018 University of Southern California, School of Pharmacy Pro Pharma Pharmaceutical Consultants Under the preceptorship of Dr. Craig Stern WHY
More informationTaiwan Generic Pharmaceutical Market Status & Issues
Taiwan Generic Pharmaceutical Market Status & Issues The 15th Annual IGPA Conference 2012 Kyoto, Japan Taiwan Generic Pharmaceutical Association Tiffany Chen OUTLINE Taiwan Pharmaceutical Market Overview
More informationUS Reimbursement Systems: Effects on R&D
US Reimbursement Systems: Effects on R&D Patricia M. Danzon, PhD Professor Emeritus The Wharton School University of Pennsylvania Theory: Optimal Reimbursement Rules to Create Efficient R&D Incentives
More informationSecond Quarter Trading Update 9 July 2010
Second Quarter Trading Update 9 July 2010 Michael Page International Second Quarter Trading Update 2010 2 Group gross profit Constant Group gross profit m m Reported exchange 2010 vs 2009 111.5 83.8 +33.1%
More informationINVESTMENT OPPORTUNITIES IN CHINA-RUSSIA-EUROPE ROUTE Presentation to UNECE PPP Conference Geneva, May 2018
INVESTMENT OPPORTUNITIES IN CHINA-RUSSIA-EUROPE ROUTE 2018 Presentation to UNECE PPP Conference Geneva, May 2018 PROPOSITION INFRAKAP HAS LAUNCHED THE EURASIAN INFRASTRUCTURE VALUE FUND FOR SOPHISTICATED
More informationFaster access of patients to new medicines Revised Transparency Directive
MEMO/12/148 Brussels, 1 March 2012 Faster access of patients to new medicines Revised Transparency Directive Today the Commission adopted the Directive relating to the transparency of measures regulating
More informationWimm-Bill-Dann Foods OJSC [NYSE: WBD]
www.wbd.com Wimm-Bill-Dann Foods OJSC [NYSE: WBD] Investor Presentation 9M 2006 Forward Looking Statements This presentation contains forward-looking statements that reflect Wimm-Bill-Dann s current views
More informationPharmaceutical Management Community Plans 2018
Pharmaceutical Management Community Plans 2018 Customer Service: (888) 327-0671 TTY: 711 Pharmacy Administration: (810) 244-1660 Introduction Pharmaceutical management promotes the use of the most clinically
More informationEconomic Update. Don Bruce Research Professor Boyd Center for Business and Economic Research. January 2019
Economic Update Don Bruce Research Professor Boyd Center for Business and Economic Research January 2019 January 2019 http://cber.haslam.utk.edu/erg/erg2019.pdf http://cber.haslam.utk.edu/ 2 National Economy
More informationBelarus Economy as part of Common Economic space: analysis and forecast
Institute of Economic Forecasting, Russian Academy of Sciences Belarus Economy as part of Common Economic space: analysis and forecast Performed by Savchishina Ksenia Institute of Economic Forecasting
More information